[144] CVS HEALTH CORPORATION SEC Filing
CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
CVS Health Corporation: Questo Form 144 segnala la proposta di vendita di 7.500 azioni ordinarie CVS tramite Merrill Lynch sul NYSE, per un valore di mercato complessivo di $532,275, prevista approssimativamente per il 08/20/2025. Il dichiarante indica che le azioni sono state ricevute come compenso da amministratore in più tranche tra il 2012 e il 2022, con lotti specifici di 1.428; 2.222; 1.546; 2.099; e 205 azioni. Non risultano vendite di titoli nei tre mesi precedenti. L'avviso riporta inoltre la consueta dichiarazione secondo cui la persona che vende non è in possesso di informazioni materiali riservate non divulgate.
CVS Health Corporation: Este Form 144 notifica la propuesta de venta de 7.500 acciones ordinarias de CVS a través de Merrill Lynch en la NYSE, con un valor de mercado agregado de $532,275, prevista aproximadamente para el 08/20/2025. El declarante informa que estas acciones se recibieron como compensación por cargos de director en varias fechas de concesión entre 2012 y 2022, en lotes específicos de 1.428; 2.222; 1.546; 2.099; y 205 acciones. No se reportaron ventas de valores en los últimos tres meses. El aviso incluye la representación habitual de que la persona vendedora no posee información adversa material no divulgada.
CVS Health Corporation: 이 Form 144는 NYSE에서 Merrill Lynch를 통해 CVS 보통주 7,500주를 매각할 예정임을 통지하며, 총 시장가치는 $532,275, 예정일은 대략 08/20/2025입니다. 제출자는 이 주식들이 2012년부터 2022년까지 여러 부여일에 걸쳐 이사 보수로 수령된 것임을 보고했으며, 구체적인 로트는 1,428주; 2,222주; 1,546주; 2,099주; 및 205주입니다. 최근 3개월 내에 매도된 증권은 보고되지 않았습니다. 통지서에는 매도인이 미공개의 중대한 불리한 정보를 보유하고 있지 않다는 통상적 진술이 포함되어 있습니다.
CVS Health Corporation : Ce Formulaire 144 notifie la proposition de vente de 7 500 actions ordinaires CVS via Merrill Lynch sur le NYSE, pour une valeur de marché totale de $532,275, prévue approximativement pour le 08/20/2025. Le déclarant rapporte que ces actions ont été reçues comme rémunération de administrateur à plusieurs dates d’attribution entre 2012 et 2022, réparties en lots de 1 428 ; 2 222 ; 1 546 ; 2 099 ; et 205 actions. Aucune vente de titres n’a été déclarée au cours des trois derniers mois. L’avis inclut la déclaration standard selon laquelle la personne vendeuse ne détient pas d’informations défavorables matérielles non divulguées.
CVS Health Corporation: Dieses Formular 144 meldet den geplanten Verkauf von 7.500 Stammaktien von CVS über Merrill Lynch an der NYSE mit einem aggregierten Marktwert von $532,275, voraussichtlich am 08/20/2025. Der Meldende gibt an, dass diese Aktien als Vorstandsvergütung in mehreren Zuteilungsdaten zwischen 2012 und 2022 erhalten wurden, in konkreten Losgrößen von 1.428; 2.222; 1.546; 2.099; und 205 Aktien. In den letzten drei Monaten wurden keine Wertpapiere als verkauft gemeldet. Die Mitteilung enthält außerdem die übliche Zusicherung, dass die verkaufende Person keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.
- None.
- None.
Insights
TL;DR: Routine Form 144 filing for director-compensation shares; sale size appears immaterial relative to company float.
The filing reports a proposed brokered sale of 7,500 shares valued at $532,275 to occur on 08/20/2025, with the holdings acquired as director compensation over 2012–2022. From a compliance perspective, the form documents the required disclosure under Rule 144 and includes the standard attestation regarding material nonpublic information. There are no reported sales in the prior three months, and the disclosure lists the acquisition dates and amounts by lot, supporting traceability to compensatory grants.
TL;DR: Transaction is small relative to outstanding shares and is unlikely to affect CVS's market valuation.
The notice shows the proposed disposition represents 7,500 shares versus 1,267,000,000 shares outstanding, indicating a negligible dilution or market impact. The aggregate value of $532,275 is immaterial to company capitalization. The origin of the shares as director compensation is disclosed, which clarifies these are insider holdings being liquidated under Rule 144 conditions rather than broad insider divestiture. No recent sales were reported that would suggest accelerated insider selling.
CVS Health Corporation: Questo Form 144 segnala la proposta di vendita di 7.500 azioni ordinarie CVS tramite Merrill Lynch sul NYSE, per un valore di mercato complessivo di $532,275, prevista approssimativamente per il 08/20/2025. Il dichiarante indica che le azioni sono state ricevute come compenso da amministratore in più tranche tra il 2012 e il 2022, con lotti specifici di 1.428; 2.222; 1.546; 2.099; e 205 azioni. Non risultano vendite di titoli nei tre mesi precedenti. L'avviso riporta inoltre la consueta dichiarazione secondo cui la persona che vende non è in possesso di informazioni materiali riservate non divulgate.
CVS Health Corporation: Este Form 144 notifica la propuesta de venta de 7.500 acciones ordinarias de CVS a través de Merrill Lynch en la NYSE, con un valor de mercado agregado de $532,275, prevista aproximadamente para el 08/20/2025. El declarante informa que estas acciones se recibieron como compensación por cargos de director en varias fechas de concesión entre 2012 y 2022, en lotes específicos de 1.428; 2.222; 1.546; 2.099; y 205 acciones. No se reportaron ventas de valores en los últimos tres meses. El aviso incluye la representación habitual de que la persona vendedora no posee información adversa material no divulgada.
CVS Health Corporation: 이 Form 144는 NYSE에서 Merrill Lynch를 통해 CVS 보통주 7,500주를 매각할 예정임을 통지하며, 총 시장가치는 $532,275, 예정일은 대략 08/20/2025입니다. 제출자는 이 주식들이 2012년부터 2022년까지 여러 부여일에 걸쳐 이사 보수로 수령된 것임을 보고했으며, 구체적인 로트는 1,428주; 2,222주; 1,546주; 2,099주; 및 205주입니다. 최근 3개월 내에 매도된 증권은 보고되지 않았습니다. 통지서에는 매도인이 미공개의 중대한 불리한 정보를 보유하고 있지 않다는 통상적 진술이 포함되어 있습니다.
CVS Health Corporation : Ce Formulaire 144 notifie la proposition de vente de 7 500 actions ordinaires CVS via Merrill Lynch sur le NYSE, pour une valeur de marché totale de $532,275, prévue approximativement pour le 08/20/2025. Le déclarant rapporte que ces actions ont été reçues comme rémunération de administrateur à plusieurs dates d’attribution entre 2012 et 2022, réparties en lots de 1 428 ; 2 222 ; 1 546 ; 2 099 ; et 205 actions. Aucune vente de titres n’a été déclarée au cours des trois derniers mois. L’avis inclut la déclaration standard selon laquelle la personne vendeuse ne détient pas d’informations défavorables matérielles non divulguées.
CVS Health Corporation: Dieses Formular 144 meldet den geplanten Verkauf von 7.500 Stammaktien von CVS über Merrill Lynch an der NYSE mit einem aggregierten Marktwert von $532,275, voraussichtlich am 08/20/2025. Der Meldende gibt an, dass diese Aktien als Vorstandsvergütung in mehreren Zuteilungsdaten zwischen 2012 und 2022 erhalten wurden, in konkreten Losgrößen von 1.428; 2.222; 1.546; 2.099; und 205 Aktien. In den letzten drei Monaten wurden keine Wertpapiere als verkauft gemeldet. Die Mitteilung enthält außerdem die übliche Zusicherung, dass die verkaufende Person keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.
FAQ
What does CVS's Form 144 filed for symbol CV S disclose?
Were the shares being sold by a CVS insider acquired through compensation?
Has the filer sold CVS shares in the past three months according to the Form 144?
How material is the proposed sale relative to CVS outstanding shares?
Which broker is handling the proposed sale of CVS shares?
